Omnicell Inc（OMCL）资讯与事件

$34.710

+0.201 (+0.58%)收盘时

OMCL 资讯

7.509-03NASDAQ.COM

Omnicell Integrates TraceLink's DSCSA Compliance Solution for Enhanced Pharmacy Operations

7.509-03Newsfilter

TraceLink and Omnicell Integration Enhances Pharmacy Management Efficiency

1.008-31Yahoo Finance

Omnicell to Present at Wells Fargo Healthcare Conference

5.008-20Fool

Omnicell Executive Sells Shares to Meet Tax Obligations

9.507-30seekingalpha

Omnicell Q2 2026 Earnings Call Highlights

9.507-30NASDAQ.COM

Omnicell Reports Significant Q2 Earnings Growth

9.507-30seekingalpha

Omnicell Q2 Earnings Report Analysis

8.506-25CNBC

Small-Cap Stocks Set for Best Performance in 30 Years

5.006-08Newsfilter

Omnicell Appoints Dan Mandoli as Senior VP and General Manager

5.004-29Fool

Avory & Company Reduces Omnicell Holdings

查看更多资讯

OMCL 事件

9/3 10:30

TraceLink Integrates Drug Supply Chain Compliance Solution with Omnicell

TraceLink announced an integration between its Drug Supply Chain Security Act compliance solution and the pharmacy inventory management systems of Omnicell. This integration is expected to enable hospitals and health systems to manage product verification, traceability, and compliance as part of everyday medication receiving workflows.

7/30 07:30

Sees 2026 Revenue at $1.23B-$1.25B

Sees 2026 revenue $1.23B-$1.25B, consensus $1.25B.

7/30 07:30

Sees Q3 Revenue of $301M-$307M

Sees Q3 revenue $301M-$307M, consensus $312.53M.

7/1 08:30

Omnicell Appoints Nnamdi Njoku as President

Omnicell announced that Nnamdi Njoku has been appointed President of the Company, effective July 1, 2026. Njoku will retain his role of Chief Operating Officer, COO, while Randall Lipps will continue to serve as Chief Executive Officer and Chairman of the Board, with a continued focus on strategic collaborations and the long-term evolution of Omnicell's solution portfolio.

5/21 12:50

FDA Alerts on Omnicell Syringe Label Issues

The FDA is aware that Omnicell has issued a letter to affected customers recommending certain syringe labels used with the i.v.STATION automated compounding system be removed from where they are used or sold. Affected devices: IVSTATION SYRINGE sterile label (40MMX40MM) - part number 258920028; IVSTATION SYRINGE sterile label (20MMX40MM) - part number 258920029. On April 10, Omnicell sent all affected customers a letter recommending the following actions: Do not use labels affected by this recall. If you or your staff locate any affected labels, immediately segregate and contact Omnicell Technical Support. Omnicell received a report of mislabeling that could affect sterile syringe labels produced using i.v.STATION. Omnicell identified inconsistent label detection behavior across i.v.STATION printers when using the sterile labels affected by this recall. Inconsistent label detection could result in unlabeled or mislabeled syringe preparations after compounding completion where the above identified sterile labels are utilized. As of April 10, Omnicell has reported no serious injuries or deaths associated with this issue.

查看更多事件

本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。